BXCL501, BioXcel Therapeutics’ experimental therapy for the treatment of agitation associated with dementia, was found to be well-tolerated and able to rapidly and sustainably lower agitation in patients with different forms of dementia, including Alzheimer’s disease. These top-line findings from TRANQUILITY, BioXcel‘s Phase 1b/2 clinical trial (NCT04251910), are expected to support the therapy’s continued development as a treatment for agitation associated with dementia. “We are very encouraged by the promising topline results from the TRANQUILITY…
You must be logged in to read/download the full post.
The post BXCL501 Led to Fast, Safe, Durable Drop in Agitation in Dementia Patients appeared first on BioNewsFeeds.